According to the Catalogue of National Strategic Emerging Industries, the biomedical industry can be divided into three categories: chemical drugs, modern Chinese medicine and biological drugs. Among them, modern Chinese medicines are divided into Chinese herbal pieces and Chinese patent medicines, and biological medicines are divided into vaccines, blood products, diagnostic reagents and monoclonal antibodies.
Supply situation of biomedical subdivision products
-The output of chemical preparations rebounded.
The output of chemical preparations in China has experienced a sharp decline caused by the outbreak in 2020, and 202 1 has rebounded. Among the five main dosage forms, the output of powder injection was 202 1, increasing by 2.5%, reaching 81.500 million bottles; Injection decreased by 12.2% to11900 million bottles; Infusion increased by 4.5%, reaching1.41.800 million bottles; Tablet PC increased by 1.5%, reaching 258.53 billion pieces; Capsules increased by 14.2%, reaching 85.52 billion capsules.
-The output of Chinese patent medicines has been declining year by year.
20 16-2022, the national output of Chinese patent medicines continued to decline. In 2022, the cumulative output of Chinese patent medicines reached 2.277 million tons, 4 1 10,000 tons less than that of 202 1.
-The wholesale volume of vaccine labels decreased slightly, and the collection volume of blood products recovered.
With the rapid development of China's vaccine market, especially after several major epidemics, the understanding of vaccines from the government to the public has been improved to varying degrees. Judging from the total number of batches issued, the number of batches of vaccines issued in China fluctuated between 20 13 and 20 19. Affected by the epidemic situation in COVID-19, 650 million vaccines were distributed in 2020, up by 15.89% year-on-year, the highest growth rate in the last decade. After the epidemic situation gradually weakens, due to the limitation of R&D technology, the number of batches distributed in China will show a steady fluctuation trend, and it will drop slightly to 670 million in 2022.
In 2006, the Work Plan on the Transformation of Plasma Collection Stations made it clear that plasma collection stations were changed from health administrative departments to blood products enterprises, and plasma collection stations established a "one-to-one" plasma supply relationship with production enterprises to speed up industry concentration. On July 18, 2007, the State Food and Drug Administration of the United States issued the Notice on Implementing the Quarantine Period of Raw Plasma for the Production of Blood Products, requiring that all plasma raw materials should be allowed to stand still for more than 3 months from July 1 2008 (known as the "window period" in the industry) before they can be put into production. Affected by the policy, the national pulp collection decreased by nearly 50% in 2007. From 2007 to 2022, influenced by the use of standardized pulp stations and people's awareness of blood donation, the amount of pulp collected in China showed a fluctuating upward trend. In 2022, the blood products industry collected more than 654.38 million tons of pulp.
Demand for biomedical products: chemicals dominate.
The market size of China's chemical and pharmaceutical industry is about 883.9 billion yuan, accounting for 47% of the market size of biomedical industry; The market size of Chinese medicine industry in China is about 467.9 billion yuan, accounting for 25%; The market size of biopharmaceutical industry in China is about 5162 billion yuan, accounting for about 28%. To sum up, at present, chemical drugs occupy a dominant position in China's biomedical industry market, but with the rapid development of biomedical industry, the proportion of biological drugs will gradually increase, and this pattern will be broken.
Segmentation trend of biomedical products: With the globalization of traditional Chinese medicine products, biopharmaceuticals have become a key growth point.
On the whole, a large part of biomedical technology in China is still in the stage of scientific research and has not been effectively transformed into productive forces, which not only wastes a lot of resources, but also makes the production practice in China fail to keep up with research and development, resulting in backward production. From the perspective of subdivided products, chemicals are still dominant, Chinese medicine products have a global development trend, and biopharmaceuticals will become the key growth point of the industry in the future.
For more research and analysis of this industry, please refer to the analysis report of Foresight Industry Research Institute "Development Prospect Forecast and Investment Strategic Planning of Biomedical Industry in China".